[4]. NCCN Guidelines Version 2.2025 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [5]. Sharman JP, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus ob...
[4]NCCN Guidelines Version 2.2025 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [5]ST-PIERRE F, MA S. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance [J]. Blood Lymphat...
我们应当积极借鉴国外研究的成果,探索我国CLL患者的特点,提高我国CLL的诊治水平。 1.Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer ...
Updates in the National Comprehensive Cancer Network (NCCN) guidelines and German CLL treatment algorithm and approvals from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) support zanubrutinib as a preferred option for the treatment of both treatment-nave and ...
2023年5月8日,根据国家药品监督管理局(NMPA)网站最新信息[1],新一代BTK抑制剂百悦泽®(泽布替尼)在中国迎来新获批,用于一线治疗成人慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)患者和成人华氏巨球蛋白血症(WM)患者。 中国临床肿瘤学会(CSCO)监事会监事长、哈尔滨血液病肿瘤研究所所长马军教授表示:“泽布替...
The median treatment-free survival (TFS) and overall survival (OS) was 16 months (4-24 months) and 180 months (145-215 months), respectively. ② The median TFS for low ( n=60), intermediate ( n=50), high ( n=45) and very high risk group ( n=60) according to the CLL-IPI ...
Acalabrutinib (CALQUENCE®) is a NCCN Category 1 preferred treatment option for CLL in the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines®)9 Acalabrutinib with or without obinutuzumab is recommended as a Category 1 preferred treatment option for patients with previously untreated...
2001 * * * 第一届先灵血液肿瘤专家论坛 喜来登度假酒店 三亚·海南 CLL的治疗新进展 NCCN/BCSH治疗指南 王椿 教授 上海市第一人民医院血液科 L Malignant lymphocytes 是造血系统的一种单克隆性B淋巴细胞增殖性疾病 西方最常见的白血病,占所有白血病的25～30%;国内发病率约为0.3/10万人。发病率随着年龄的增加...
COPIKTRA (duvelisib) is an oral treatment for chronic lymphocytic leukemia or small lymphocytic leukemia (CLL or SLL). See Full Prescribing Information including BOXED WARNING. Copiktra is indicated for the treatment of adult patients with relapsed or re
CLL and SLL core indications of BTK inhibitors; zanubrutinib included in NCCN guidelines for CLL and SLL. Given the results from the ALPINE and SEQUOIA studies, the National Comprehensive Cancer Network (NCCN) guidelines now recommend zanubrutinib for first-line treatment except for relapsed CLL...